Your Location：Home >Products >Fine Chemicals >1310726-60-3
Appearance:powder
Throughput:100|Kilogram|Month
pd_productuse:intermediate
Delivery Time:in stock
Purity:98% purity
density 1.56±0.1 g/cm3(Predicted)
pka 11.89±0.60(Predicted)
use
Upadacitinib is a JAK1 selective inhibitor being investigated to treat rheumatoid arthritis, Crohn's disease, ulcerative colitis, atopic dermatitis, psoriatic arthritis, axial SpA and Giant Cell Arteritis and Takayasu Arteritis.
Introduction
Upadacitinib (ABT-494) is a Janus kinase 1 (JAK1) inhibitor currently being developed by AbbVie for the treatment of rheumatoid arthritis (RA), Crohn’s disease, ulcerative colitis, atopic dermatitis, and psoriatic arthritis. It is also being investigated as a potential treatment for people with active ankylosing spondylitis (AS).
AS is an inflammatory, progressive autoimmune disease that affects the joints of the spine. As the disease progresses, calcium deposits form where ligaments attach to the bones that form the spine, leading to reduced flexibility of the back.
use
Upadacitinib is a potent and selective Janus kinase (JAK) 1 inhibitor with an IC50 of 43 nM.
CAS：517920-73-9
CAS：881681-00-1
CAS：12079-65-1
CAS：481-49-2
